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1. Introduction
Phenomena of human environmental-genetic mismatch led to epidemic of chronic non-infectious
degenerative pathologies known as civilization diseases with the Diabetes Mellitus (DM) among the
most widespread (Kopp, 2019). They were rather unobserved in hunter-gatherers but they became
commonness with continuous intensification and expansion of urban environments, and consequent
drastic switch of the lifestyle. They cause important health complications and serious consequences
for the modern economies, and moreover according to the estimates the problem will keep growing
with the increasing disease prevalences during next decades (https://www.who.int/diabetes/global-
report/en/ Accessed August 12, 2020).
1.1. Neuropathies and Neuropathic Pain in DM
One of the most frequent complications of diabetes – observed in 60% of cases - is neuropathy
(England, 2013), particularly in it’s polyneuropathic form  (Boulton & Malik, 1998; Rodica Pop-
Busui et al.,  2017). Diabetic Polyneuropathy (DPN) is described as an axonal length-dependent
nerve damage with loss of distal sensation, and with characteristic sensory loss progression in the
arms and legs called as a “glove and stocking” mode  (England, 2013).  It was reported to reach
around 16% – 20% of diabetic populations in Europe  (Davies et al., 2006; Sadosky et al., 2008;
Veves et al., 2008), 20% - 37% in Western Asia (Al-Mahroos & Al-Roomi, 2007; D. D. Wang et
al., 2014) and around 50% in US countries (45% of non-insulin-dependent DM and 54% of insulin-
dependent DM)  (Dyck et al.,  1993). The diagnosis of neuropathy in patients is standardly done
through sensory and motor nerve conduction study, quantitative sensory testing, confocal corneal
microscopy or skin biopsy (Solomon Tesfaye et al., 2010). The latter one allows monitoring of the
state of degeneration of intra-epidermal nerve fibers (IENF) which simultaneously correlates with
clinical phenotype and with outcomes of other  neurophysiological examinations  (Devigili  et al.,
2008). Skin biopsy assessment is though a significant instrument providing important  information
on the pathogenesis, character and progression of neuropathy.
Majority of DPN patients may continue without manifesting any of the symptoms that could impede
their  everyday  life  (asymptomatic  diabetic  neuropathy)  but  still  around  1/3  of  them  develop
disabling neuropathic pain (NP) – the main cause of morbidity in DM. In UK the prevalence of
painful form of diabetic neuropathy among diabetic individuals was estimated for 21% (Abbott et
al., 2011). In the same population 34% of studied DM patients had painful neuropathy symptoms in
the absence of clinical diagnosis of diabetic neuropathy (DN) (Abbott et al., 2011). Another studies
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conducted always on UK diabetic patients estimated prevalence specifically of pure neuropathic
pain to 19%, of chronic form painful peripheral neuropathy to 16.2% and of mixed pain to 7.4%
(Daousi et al., 2004; Davies et al., 2006). According to meta-analysis results, between 5.8–34% of
diabetic patients from European countries suffered from NP (Alleman et al., 2015). The estimates
for Korea (Kim et al., 2014) and Japan (Tsuji et al., 2013) were comparable reaching respectively
14.4% and 22.1% of DM cohorts, while the prevalence assessed in patients from Saudi Arabia
attained 65.3% (Halawa et al., 2010).
Neuropathic  pain  is  distinguished  from  other  types  of  pain  due  to  its  particular  character  –
simultaneous  sensory  loss  and  pain,  with  or  without  symptoms  of  sensory  hypersensitivity  as
allodynia or hyperalgesia  (Feldman et al.,  2017). The sensory alterations may be observed as a
response to one or  more different  modalities  of stimuli:  touch,  pressure,  pinprick,  cold or  heat
(Jensen & Finnerup, 2014). NP in DN can reach various intensity levels and can have different
forms usually described as “burning”, “electric”, “sharp”, “shooting”, “aching” (Galer et al., 2000).
Thus generally it has serious adverse effects on performance of quotidian routines, on sleep and on
general well-being of individual  (Alleman et al., 2015). Furthermore, the available treatments for
NP are highly inefficient – in around 50% of cases the achieved pain relief is at best 50% (Attal et
al., 2010) and often they cause deleterious side effects (Rodica Pop-Busui et al., 2017).
Overall,  why some of  the  DN patients  develop painful  form of  neuropathy while  others  (with
similar or even more severe degree of a nerve damage) – painless, it remains unclear and continues
intriguing specialists of the field. Another fascinating question is how to predict and identify the
individuals that are in higher risk to develope NP comparing to standard population exposed to
hazards of similar levels (Lauria et al., 2014).
1.2. Risk factors of neuropathic pain in DPN
Glycemic  control  and  duration  of  diabetes  are  main  risk  factors  for  the  development  of  DPN
(Franklin et al., 1990; Maser et al., 1989; S. Tesfaye et al., 1996). This is valid for both types of
diabetes, though type 2 DM (T2DM) increases the probability of DPN onset  (Van Acker et al.,
2009). Additional favorable conditions that have been described up-to-date include hypertension,
obesity, high levels of triglycerides and smoking (Andersen et al., 2018; Callaghan et al., 2018; R
Pop-Busui et al., 2013).
On the other hand, the risk factors specific for neuropathic pain in DM are still not well identified
and they are largely overlapping with the elements associated with DM and/or DN. Demographics,
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clinical phenotype, lifestyle with habitat and genetics may substantially contribute to increased risk
of NP  (Hébert et al.,  2017). Among the demographic characteristics,  higher age  (Halawa et al.,
2010; Jambart et  al.,  2011; Van Acker et  al.,  2009; Ziegler,  Rathmann, Dickhaus, et  al.,  2009)
(particularly above 50 years) and female sex (Abbott et al., 2011; Erbas et al., 2011; Halawa et al.,
2010; Jambart et al., 2011; Pai et al., 2018; Raputova et al., 2017) were identified as risk factors for
neuropathic  pain.  The commonly  observed  greater  prevalence  of  painful  manifestations  among
women may be the reflection of possible joined sex-related nuances of biologic and psychosocial
nature, and interaction between them (Hébert et al., 2017). Even though the prevalence of painful-
DPN differs among the countries (as referred above, see 1.1 Neuropathies and Neuropathic Pain in
DM) no evidence  on association  between the  ethnicity  and NP in  diabetic  patients  was found
(Halawa et al., 2010; Harris et al., 1993; Sorensen et al., 2002; Themistocleous et al., 2016).
Regarding  the  clinical  factors,  according  to  available  studies  it  is  not  clear  if  susceptibility  to
develop painful-DPN could be associated with the type of DM (Abbott et al., 2011; Jambart et al.,
2011) but it was shown to increase with the duration of diabetes (Jambart et al., 2011; Sorensen et
al., 2002; Van Acker et al., 2009). Poor glycaemic control  (Algeffari,  2018; Harris et al., 1993;
Themistocleous et al., 2016), elevated glycosylated haemoglobin (HbA1c) levels (Algeffari, 2018;
Themistocleous et al.,  2016), low high-density lipoprotein (HDL) cholesterol  (Van Acker et al.,
2009), high triglyceride levels (Van Acker et al., 2009), coexisting cardiovascular diseases (Jambart
et al., 2011; Ziegler, Rathmann, Dickhaus, et al., 2009), hypertension (Harris et al., 1993; Jambart et
al.,  2011),  nephropathy  (Van  Acker  et  al.,  2009),  glycosuria  (Harris  et  al.,  1993) were  also
identified  as  clinical  factors  contributing  to  painful-DPN.  Nevertheless,  since  those  are
complications closely related to diabetes, it is not clear if they directly rise the NP risk or rather they
are tightly coexisting conditions.
Some of the components of the lifestyle – the term that broadly embraces one’s diet and alimentary
habits, physical activity, nature of daily executed profession, living conditions and environment -
also were found to contribute to painful-DPN. Particularly body mass index (BMI) - especially
reaching  levels  of  obesity  above  30  kg/m2,  weight  and  waist  circumference  were  shown  to
significantly increase the risk of NP onset in diabetic patients (Van Acker et al., 2009; Ziegler et al.,
2018;  Ziegler,  Rathmann,  Meisinger,  et  al.,  2009).  Psychosocial  profile  including  depression,
anxiety,  quality  of  life  and  social  interactions,  seems  to  be  also  related  to  neuropathic  pain
(D’Amato et al., 2016; Gore et al., 2005; Raputova et al., 2017). However, those factors must be
interpreted with caution since the temporal relationship between them and painful manifestations in
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majority of the cases is not determined. Instead, there was found no evidence that smoking and
alcohol consumption could be associated with NP (Abbott et al., 2011; Halawa et al., 2010; Harris
et al., 1993; Sorensen et al., 2002; Spallone et al., 2011; Ziegler, Rathmann, Meisinger, et al., 2009).
Study by Jambart et al  (Jambart et al., 2011) indicated that also habitat could be one of the risk
factors for painful-DPN since the corresponding odds ratios of the pathology differed significantly
between  Egypt  and  two  other  Middle  East  countries:  Gulf  States  and  Lebanon,  reaching
respectively 0.44 and 0.66.
The first evidence on involvement of genetics in the development of painful-DPN came from a
prospective survey study carried on a group of 105 patients (mostly Caucasians – 93%) with painful
diabetic neuropathy (Galer et al., 2000). 56% of cases reported having relatives of first or second
degree with the same pathology. To date,  two genome-wide association studies were published,
both involving the same diabetic cohort but applying different phenotype definitions (W. Meng et
al.,  2015; Weihua Meng et al.,  2015). Thus, in total  three chromosome loci emerged and were
proposed as NP risk factors: i) sex-independent 8p21.3 cluster, located next to the gene GFRA2; ii)
female-specific 1p35.1 cluster, with the ZSCAN20/TLR12P gene; iii) male-specific 8p23.1 cluster,
positioned next to  HMGB1P46 gene. Moreover, according to two recent studies using candidate-
gene approach, there is a significant association between painful experience in DM and SCN9A (Q.
S. Li et al., 2015) and OPRM1 (Cheng et al., 2010) variants.
1.3. DNA methylation and DN
While one’s genetic heritage is at this point considered as immutable, epigenetics is a powerful
mechanism that is able to control and alter the expression of genes. Through DNA methylation,
histone acetylation and non-coding RNAs interference, epigenetics responds to external stimuli and
eventually  may  trigger  or  prevent  the  onset  of  certain  diseases  to  which  one  is  genetically
predisposed as for example T2DM and its complications  (Agardh et al., 2015; Bansal & Pinney,
2017; Liu et al., 2014).
Epigenetics and particularly DNA methylation in diabetic neuropathy only very recently has been
studied in humans. Although limited in sample sizes, published works are concordant in providing
the evidence on altered DNA methylation patterns observed among DN patients and in proposing it
as a new risk factor for this disease. 
Zhang and colleagues  (Zhang et al., 2019) assessed DNA methylome of white blood cells of 186
T2DM patients among who 100 and 86 were positive and negative for DPN diagnosis respectively.
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Methylation  levels  were  measured  using  high-performance  liquid  chromatography-tandem mass
spectrometry. According to published results, leukocytic genomic DNA was hypomethylated in the
DPN cases comparing to non-DPN controls. Additionally it was observed that the degree of DNA
methylation decreased with the increasing severity of the disease, with duration of diabetes and with
BMI  of  the  individuals.  Authors  suggest  that  this  can  be  related  to  both  alterations  in  the
expressions of the methyltransferases DNMT3a and DNMT3b and to the reduction of one-carbon
unit (vitamin B12 and folic acid) due to T2DM.
Another evidence on contribution of epigenetic mechanisms in onset and development of diabetic
neuropathy came from study involving DPN patients with T2DM from Guo and colleagues (Guo et
al.,  2019).  Genome-wide DNA methylation was evaluated in  sural  nerve biopsies with reduced
representation  bisulfite  sequencing  (RRBS)  technique.  Two  extreme  DPN  phenotypes  were
compared:  six  degenerators  and  six  regenerators,  identified  according  to  the  two  subsequent
outcomes of biopsies separated in time by 52 weeks.  They represent  respectively  patients  with
significantly reducing or improving nerve fibre counts. In total there were 3,460 CpG sites (55%
hypo-  and  45%  hyper-methylated)  that  were  found  differentially  methylated  between  the
phenotypic groups and which mapped to 2,835 unique genes. Two of three selected targets (within
DYSPL2 and  miR3138 genes)  were  successfully  validated  using  loci-specific  pyrosequencing
methylation  analyses.  Nervous  system  development,  axon  guidance,  glycerophospholipid
metabolism  and  MAPK  signalling  were  the  main  biological  pathways  that  emerged  from  the
enrichment analysis, indicating that sural nerve methylation state could be involved in modulation
of regenerative capacity of the fibres in DPN.
The same research  team investigated  methylome in  T2DM patients  with  DPN, comparing  two
extreme  phenotypes:  21  and  32  individuals  respectively  with  the  highest  (more  severe  health
condition)  and  the  lowest  HbA1c  levels  (Guo  et  al.,  2020).  As  previously  they  studied  DNA
methylation  in  sural  nerve  biopsies  using  RRBS approach.  2,066 CpG sites  (mapping to  1489
unique genes with valid official symbols) were detected as differentially methylated, of which 57%
were hypo- and 43% hyper-methylated in group with high HbA1c levels relative to group with low
levels. Beside of modified methylation patterns, 71 of unique genes (4,7%) were found to have also
altered expression, indicating at the same time the contribution of genetic-epigenetic interplay to
DPN  progress.  The  pathways  that  emerged  from  network  analysis  performed  on  shared
differentially methylated and expressed genes were involved in immune response – known to be
closely related to neuropathies (Rodica Pop-Busui et al., 2016).
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Although peripheral neuropathy is the most common class of neuropathy in diabetes mellitus, there
are also other forms of neurological complications that often remain under-diagnosed but still lead
to very severe health consequences. Cardiovascular Autonomic Neuropathy (CAN) is one of such
cases, reaching the prevalence of around 60% among diabetic patients (Pan et al., 2019). Recently,
whole-genome DNA methylation  analysis with Infinium Methylation EPIC BeadChip array was
used to assess and compare methylome in peripheral blood cells of 24 patients with and 25 without
CAN in DM type 1  (Gastoł et al., 2020). Three genomic regions were identified as differentially
methylated, of which two (BRSK2 (intron 1) and CLDN4 (5’UTR)) were hypo-methylated, and one
(NINJ2 (intron 1)) was hypermethylated among CAN cases. Additionally, epigenetic modifications
observed in  CLDN4 and  NINJ2 was successfully confirmed to have biological significance since
they showed decreased expression in CAN positive individuals. 
One of the genes that is the most extensively described among methylation studies of pain-related
phenotypes is transient receptor potential ankyrin 1 (TRPA1). This gene was firstly associated with a
heat sensitivity by Bell and colleagues  (Bell et al., 2014). They found that  TRPA1 promoter was
hypermethylated in twins that had lower heat pain suprathresholds comparing to their co-twins. In
another study, similar hypermethylation pattern was discovered in subjects that were more sensitive
to  pressure  and  mechanical  pain  (Gombert  et  al.,  2017).  The  primary  evidence  regarding  the
epigenetics of TRPA1 particularly in neuropathic pain came from work of Sukenaga and colleagues
(Sukenaga  et  al.,  2016),  who  examining  12  chronic  pain  patients  showed  positive  correlation
between  hypermethylation  of  this  gene  and  number  of  NP  symptoms.  The  observation  was
reproduced  in  another  study  involving  subjects  with  neuropathic  pain  (n  =  18),  with  non-
neuropathic pain (n = 8) and without pain (n = 22), recruited from group of chronic pain patients
and of lung cancer patients scheduled for thoracic surgery  (Takenaka et al., 2020). According to
published results, five of six evaluated CpG sites were significantly hypermethylated in neuropathic
pain  subjects  when compared  to  two other  phenotypic  groups  (with  non-neuropathic  pain  and
without pain).
To our knowledge, this is a pioneering genome-wide DNA methylation study exploring epigenetic
signature of neuropathic pain in unique populations of T2DM patients that received diagnosis of
diabetic neuropathy basing on evaluation of skin biopsy.
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2. Aims
The  aim  of  European-funded  project  PAIN-Net  “Molecule-to-man  pain  network”  is  to  better
understand the experience of pain and individual susceptibility to it through the collective effort of
multidisciplinary  scientific  board.  Particularly,  the  comprehensive  characterization  of  painful
neuropathy and cancer pain profiles, (encompassing clinical, genetic, neurophysiologic, skin biopsy
and the epigenetic assessment), and the integration of multiomic data produced and shared within
the consortium, intended to allow identification of patients that are at higher risk to develop chronic
painful manifestations and to recognize individual responsiveness to analgesics. In the framework
of  PAIN-NET,  the  aim of  the present  thesis  was to  describe  the DNA methylation  patterns  in
painful and painless type 2 diabetic neuropathy patients and to identify a set of candidate genes
potentially  associated with the experience of pain.  Identified short  list of most promising genes
would  serve  for  further  validation  of  epigenetic  signature  in  independent  cohorts  that  include
individuals presenting pain-related phenotypes.
Furthermore we tested the hypothesis that neuropathic pain in DN contributes to acceleration of
biological age estimated with DNA methylation.
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3. Study Design
The design of the present DNA methylation analysis of NP in T2DM is aimed at determining a set
of potential  candidate genes with different methylation patterns in painful and painless patients.
Identified short list of most promising loci was validated in independent pain-related whole-genome
methylation dataset available at UNIBO and produced previously in a frame of a study on migraine
(Terlizzi et al., 2018). The selection of interesting candidates will be also used in future validation
of epigenetic signals in independent cohorts of individuals presenting various painfull phenotypes.
This study was complemented with evaluation of biological age expressed by different prediction
models based on DNA methylation data.
Two independent cohorts were considered in the experimental design: PROPGER and PROPENG.
Both cohorts were provided by the partners of PAIN-Net ITN Consortium and involved diabetic
neuropathy  patients.  PROPGER  cohort  was  provided  by  University  of  Maastricht  (NL)  and
consisted of painful and painless DN individuals recruited in German Diabetes Center in Düsseldorf
(Germany). Those individuals represented principally German population (93%). PROPENG cohort
consisted of DN  subjects provided by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta in
Milan (Italy) and recruited at Manchester University (UK) predominantly from English population.
A  consistent  clinical  assessment  and  characterization  of  phenotypes  were  a  crucial  factor
guaranteeing  successful  accomplishment  of  this  study.  Therefore,  within  PAIN-Net  consortium
uniform diagnostic approach was defined, accepted and applied by all the members. According to
this agreement, neuropathy was determined basing on the result of skin biopsy and patients  were
considered as “painful” if they experienced neuropathic pain for more than 1 year and if their pain
intensity reached score 4 or higher on the Numeric Rating Scale (NRS).
The  study  design  foresaw  assessment  of  the  genome-wide  DNA  methylation  using  Illumina
Infinium MethylationEPIC BeadChip technology. The adopted strategy allowed the identification
of  pain-associated  regions  through  validated  pipeline  developed  and  originally  implemented  at
UNIBO, in charge of this analysis within PAIN-Net project.
3.1. Sample Selection
The  populational  genomic  background  is  heteregenous  since  it  is  continously  shaped  by
demographic  history,  neutral  and  adaptive  evolution  and  the  complex  interplay  between  them
(Sazzini et  al.,  2016). Genetic variations are closely linked to DNA methylation and can easily
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influence the epigenetic patterns, introducing in this way a confounding variability in the data that
should not be neglected  (Gutierrez-Arcelus et  al.,  2013).  Therefore,  in order to reduce the bias
coming from populational  genetics  it  was opted to include exclusively  individuals  of European
ethnicity and to analyze the cohorts from German and English populations separately.
Diabetes mellitus of type 1 and of type 2 involve distinct biological mechanisms and have different
genetic predisposition factors (Grant et al., 2010), and as such they could be a source of additional
variability in studied phenotypes. Thus, only DN patients diagnosed with T2DM were selected and
epigenetically assessed.
Whenever  possible,  it  was  attempted  to  match  painful  and  painless  samples  regarding  the
chronological  age and sex since  both factors  were  shown to alter  the DNA methylation  levels
(Bacalini et al., 2015; Davegårdh et al., 2019).
3.2. Profiles of Study Cohorts
PROPGER cohort involved 72  Painful Diabetic Neuropathy (PDN, mean age 68.8 years; age
range 48 - 83) and 67  Painless Diabetic Neuropathy (PLDN, 69.7 mean age; age range 49 - 84)
patients  (Table  1).  The  phenotypic  groups  did  not  differ  significantly  in  mean  age  (p-values
obtained from two-sided T-test = 0.554).
The duration of T2DM was indifferent between painful and painless group, ranging between 0 – 46
and 0 – 44 years respectively and reaching in average 13.6 years. Typically DN individuals were
diagnosed with neuropathy since 6 years, with PDN subjects starting suffering from the pathology
slightly earlier than PLDN, however the difference of 1.4 year did not reach the level of statistical
significance (p-values from two-sided  T-test = 0.202). In  majority of the patients (68%) diabetes
was medically recognized prior to neuropathy. 27% of individuals received as primary the diagnosis
of neuropathy.
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Table 1 Size, sex, age, duration of T2DM and of neuropathy for each phenotypic group within PROPGER cohort are reported. PDN:
Painful Diabetic Neuropathy; PLDN: Painless Diabetic Neuropathy; T2DM: Type 2 Diabetes Mellitus; SD: Standard Deviation.
PDN PLDN
Number of samples (%) 72 (52%) 67 (48%)
Sex (Females / Males) 15 / 57 14 / 53
Age Average ± SD (years) 68.8 ± 9.0 69.7 ± 9.1
T2DM Duration (years) 13.5 ± 10.3 13.6 ± 9.2
Neuropathy Duration (years) 6.9 ± 6.1 5.5 ± 6.5
In the PROPENG cohort 27 painful (PDN, mean age 62.1 years; age range 46.2 – 78.1) and 65
painless (PLDN, mean age 65.0 years; age range 40.9 – 78.1) DN patients were included (Table 2).
There were no significant differences in mean age between the groups (p-values obtained from two-
sided T-test = 0.169).  On average, painful subjects suffered from T2DM for the last 13.4 years
(duration range 0.5 – 38.8 years) while painless individuals - for 9 years (duration range 0.2 – 28.0
years). Mean span of T2DM among PDN patients was about four years longer than within PLDN
group (Welch two-sided T-test p-value = 0.041).
Table 2 Size, sex, age and T2DM duration for each phenotypic group within PROPENG cohort are reported. PDN: Painful Diabetic
Neuropathy; PLDN: Painless Diabetic Neuropathy; T2DM: Type 2 Diabetes Mellitus; SD: Standard Deviation.
PDN PLDN
Number of samples (%) 27 (15%) 65 (37%)
Sex (Females / Males) 9 / 18 19 / 46
Age Average ± SD (years) 62.1 ± 9.1 65.0 ± 9.0
T2DM Duration (years) 13.4 ± 9.8 9.0 ± 7.0
3.3. DNA Methylation Study
DNA extraction and experiment preparation
DNA was extracted from whole blood specimens of DN patients using Puregene Blood Quiagen kit
following the steps of corresponding protocol. All the samples were quantified with Qubit dsDNA
BR (Broad Range) Assay kit on Qubit Fluorometer by Thermo Fisher Scientific and verified to
contain ≥ 1000ng of DNA, i.e. the amount required for a methylation assay. 1000 ng of genomic
DNA were  normalized  in  50µL of  H2O and were  used  in  bisulfite  conversion  with  EZ DNA
Methylation  Kit  (Zymo Research)  following  the  manufacturer’s  instructions.  DNA methylation
experiment was performed with Infinium HumanMethylationEPIC BeadChip (Illumina) according
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to  original  protocol.  Within  each  array  the  samples  and  phenotypic  groups  were  accurately
randomized.
Preprocessing of raw data
All the handling and manipulation of files were performed in Linux environment. Output raw data
files (.idat format) from  the two experiments were  separately preprocessed using  minfi package
within R software (version 3.6.1).  As summarized on Figure 1, the applied pipeline conduced the
files  through  normalization,  cleansing  step,  quality  control  and  filtering  according  to  the
recommendations of Maksimovic et al. (Maksimovic et al., 2016). Poor quality samples with mean
detection p-value < 0.05 were removed from the analysis. The raw values of intensities in green and
red  channels  were  normalized using  functional  approach  removing  undesired  variation  with  a
regression model of explained variability based on the control probes included in the array (using
preprocessQuantile function from minfi package). Probes that failed in at least one of the samples
(i.e. presented detection p-value > 0.01), those located on sex chromosomes and those mapping to
loci  with  SNPs  were  eliminated.  Additional  filtering  steps  were  implemented  according  to  the
recently  published  recommendations  regarding  the  Illumina  arrays  therefore  consequently  were
removed: i) probes with potential hybridization issues since aligning to the human genome hg19 in
multiple sites (Benton et al., 2015); ii) non-specific and cross-reactive HM450K probes (Chen et al.,
2013);  iii)  cross-reactive and variant containing EPIC-specific  probes  (Pidsley et  al.,  2016);  iv)
probes suggested to be masked from mapping according to Zhou W et al. (Zhou et al., 2017) due to
non-unique 3’-subsequences, presence of INDELs or color-channel-switching SNPs etc.  Finally,
beta  values estimating  the  methylation  levels  as  a  ratio  of  methylated  to  unmethylated  alleles
intensities, ranging between 0 (totally unmethylated) and 1 (totally methylated), were retrieved from
processed  GenomicRatioSet and  used  in  subsequent  identification  of  differentially  methylated
regions (DMRs).
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Figure 1 Summary of  preprocessing pipeline of the raw methylation data inlcuding a sequence of normalisation, 
cleansing, quality control and filtering steps.
Applying the filtering criteria described  above, all the samples from PROPGER and PROPENG
cohorts were retained, while in total 211,458 and 214,251 probes were removed from respective
datasets (Table 3).
Table 3 Number of probes removed in filtering steps during processing EPIC methylation results from PROPGER and PROPENG
experiments.
Probes: PROPGER PROPENG
with detection p-value > 0.01 18310 21021
located on X- and Y-chromosomes 18298 18263
mapping to loci with SNPs 27442 27479
multi-mapping and/or non-specific cross-reactive on HM450K array 32436 32462
cross-reactive and variant-containing on EPIC array 95011 95156
additionally masked 19961 19870
In total 211458 214251
Differential analysis and identification of candidate genes
The  epigenetic  landscape  of  pain  in  PROPGER  and  PROPENG  cohorts was  delineated
implementing an already validated pipeline developed by Bacalini et al.  (Bacalini et al.,  2015).
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Figure  2 summarizes  the  applied  workflow  which  passes  through 3 stages:  1)  classification  of
probes, 2) their grouping and eventually 3) statistical analysis. During classification step each probe
was assigned to one of four groups (A-D), depending on  its genomic localization (i.e. CpG-rich
regions and genic DNA sequences) as visualized on Figure 3.
Figure  2 Graphical  representation of the analytical pipeline to select differentially methylated  regions, proposed by
Bacalini et al. (Bacalini et al., 2015)
Figure 3 Summary of the annotation of probes to separate classes according to their genomic localization. (Figure from
(Bacalini et al., 2015))
Subsequently probes were annotated and grouped into blocks of probes (BOPs), according to their
proximity along the genome. The CpG island is a genomic region with CG/GC content ratio above
0.6 (Cross & Bird, 1995) and it is formed of central island body extended with shelfs and shores
located respectively on it’s both (N- and S-) extremities as presented in Figure 4. These CpG units
constitute individual BOPs covered by the probes of classes A and B. The principle of this grouping
is the experimental evidence of correlation of DNA methylation levels of neighboring CpGs within
a span of 250 – 500 bp  (Y. Li et al.,  2010),  suggesting that this concordant alteration of DNA
methylation level likely may have a biological effect. Applied pipeline initially assumes that CpG-
rich regions (class A and B) exhibit condensed distribution of methylation sites and this statement is
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further verified and corrected during the statistical analysis. In a case of class C - non CpG-rich
genic regions – BOPs are delimited by genic sequences, presupposing that methylation status of
CpGs within a single gene shall be directed to reach the same biological effect. Since probes of
class D are disperse along non-genic sequence, they remain ungrouped as single players. Described
assignment of BOPs is summarized in Figure 5.
Figure 4 Sketch of general  architecture of CpG island, with its  specific  regions.  (Retrieved from (Bibikova et al.,
2011))
Figure 5 Representation of organization and assignment of BOPs. (Retrieved from (Bacalini et al., 2015))
Afterwards,  for  each  identified  BOP  the  average  base-pair  distance  of  adjacent  CpGs  was
calculated.  The statement  on epigenetic  correlation within 250 – 500 bp genomic intervals  was
verified and served as a threshold to determine the statistical approach. If computed distances were
below 500 bp, the probes within this particular BOP were analyzed with region-centric approach
using sliding window MANOVA. Contrary, if the base-pair intervals were longer, or there were
only 2 or less probes within the single BOP, they were considered as a singletons and were analyzed
applying ANOVA (Figure  6).  Eventually all  estimated  p-values were corrected for multiple tests
with Benjamini–Hochberg (BH) procedure.
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Figure 6 BOP-specific identification of statistical approach that shall be applied and proper statistical analysis to be
applied.
In  order  to  identify  the  promising  pain-related  genes  and  select  the  candidates  for  further
validations, the most reliable epigenetic signals were searched. For this purpose, CpG sites were
filtered according to following criteria:
a) significant nominal p-value from ANOVA test in PROPGER cohort;
b) absolute value of methylation change in PROPGER > 1%;
c) significant nominal p-value from ANOVA test in PROPENG cohort;
d) concordant direction of methylation change observed in both cohorts PROPGER and PROPENG.
In this analysis, consistently the statistical significance level of 0.01 was used.
To further explore obtained results, additional analyses were performed:
- inspection of independent public methylation datasets related to pain-related phanotypes (heat pain
sensitivity (Bell et al., 2014); fibromyalgia (Ciampi de Andrade et al., 2017));
- inspection of methylation dataset already available from previous studies (migraine (Terlizzi et al.,
2018));
-  methylation standard deviation distribution analysis;
-  multidimensional scaling (MDS).
In order to verify if found epigenetic patterns could be reproduced in other pain-related phenotypes,
DNA methylation  levels  in  selected  candidate  genes  were reviewed in three independent  DNA
methylation datasets: i) heat pain sensitivity (Bell et al., 2014); ii) fibromyalgia (Ciampi de Andrade
et al., 2017); iii) headache syndromes (Terlizzi et al., 2018). First of the datasets came from a study
assessing 20 monozygotic female twin pairs discordant for heat pain suprathreshold. The second
investigated DNA methylation in 24 female cases of fibromyalgia and 20 sex- and age-matched
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controls. Both datasets were generated using Infinium Human Methylation 450K BeadChip. The
migraine  dataset  was  a  prospective,  observational  study  that  included  three  subgroups  of
individuals: patients with chronic migraine and medication overuse headache (MOH, 25), episodic
migraines  (EM,  18)  and  healthy  controls  (HC,  13).  The  methylation  data  was  produced  with
Infinium Methylation EPIC platform.
Methylation standard deviation distribution analysis was performed in order to assess the epigenetic
drift in studied cohorts and to evaluate if it could be related to the experience of neuropathic pain.
Methylation  drift  concept  embraces  naturally  occurring  age-related  alterations  within  the
methylome  that  are  environmental  and  random effects  (Jones  et  al.,  2015).  This  phenomenon
manifests across population as continuously increasing dysregulation of methylation patterns with
the age (Heyn et al., 2012; Talens et al., 2012). Thus, changes in epigenetic variance were assessed
through computation of standard deviation for each of methylation probes of EPIC platform and the
differences  between  PDN  and  PLDN  samples  were  evaluated  with  two-sample  Kolmogorov-
Smirnov (KS) test (statistical significance level at 1%). The results were presented as density plots
visualizing the distribution of standard deviation values after logarithmic transformation.
Multidimensional scaling approach was applied to examine the dissimilarity between painful and
painless phenotypes and assess if selected set of CpG sites brought out the most discriminating
epigenetic  signal  that  could  help  to  clusterize  the  subjects  according  to  clinical  phenotypes  or
eventually  could  indicate  presence  of  even  more  homogeneous  phenotypic  sub-groups.  The
classical method known as principal coordinates analysis was implemented (Gower, 2005). Visual
representation  of  MDS results  was  created  projecting  the  distances  between  the  samples  in  2-
dimensional space.
Biological age estimation
DNA  Methylation  Age  Calculator  (https://dnamage.genetics.ucla.edu/)  developed  by  Horvath
(Horvath, 2013) was used to assess epigenetic clocks for painful and painless DN patients. These
clocks directly correlate with chronological age, can predict lifespan and relate to many age-related
health conditions. They are based on DNA methylation values and through algorithms involving
beta values measured at specific CpG sites estimate the biological age of samples. Among propsed
epigenetic  clocks  there  are:  standard  Horvath’s  “pan-tissue”  clock  (Horvath,  2013),  Hannum’s
blood-specific clock (Hannum et al., 2013), skin and blood clock that was developed for fibroblasts
and other cell types used in ex vivo studies (Horvath et al., 2018), the PhenoAge which is enriched
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in component of clinical measures of phenotypic age reflecting differences in lifespan and healtspan
(Levine et  al.,  2018), and the GrimAge (incorporating estimates of seven different  proteins and
hormones, along with predicted number of smoked cigarette packs per year) claimed to have out-
standing predictive potential regarding mortality and number of serious health complications  (Lu,
Quach, et al., 2019).
Preprocessed and normalized PROPGER and PROPENG methylation datasets were independently
submitted to online tool. The results returned included a set of estimates characterizing a biological
state of each individual and giving a broad view on biological functions (that change with age in
standard population) and their eventual alterations in studied phenotypes. Detailed description of all
calculated DNAm-based  variables is provided in Table 6 in annexes.
Prior to subsequent analysis the eventual outliers were removed, i.e. samples for which DNAmAge
estimates were below Q1 – 1.5IQR or above Q3 + 1.5IQR, where Q1 – first quartile, Q3 - third
quartile, IQR - interquartile range. Thus, four and one samples were excluded from PROPGER and
PROPENG cohorts respectively. The distributions of all epigenetic measures were examined and it
was verified that the assumption of normal distribution could be applied to all analyzed variables.
Finally,  in  order  to  examine  the  impact  of  neuropathic  pain  on  biological  age,  DNAm-based
estimates were used in multiple linear regression approach to explore biological age acceleration.
Specifically, the differences in each DNAm estimation between painful and painless samples were
assessed  through  linear  regression  model  correcting  for  chronological  age  and  sex:  lm(DNAm-




The analysis involved in total 139 samples from PROPGER cohort (72 painful and 67 painless) and
92 from PROPENG cohort  (27 painful and 65 painless).  The list  of interesting  candidates  was
generated by selecting CpGs that reached statistical significance level (nominal ANOVA p-value <
0.01) and presented methylation change above 1% within PROPGER cohort, and which in the same
time resulted significant also in PROPENG and showed the same direction of methylation change.
In total there were 27 sites that passed established filters of which 8 were non-genic. Resulting list
of 19 unique genes was further inspected in details as summarized in Table  4. 12 of the selected
candidates  were  found hypo-methylated  in  painful  patients  while  7  were  hyper-methylated.  12
(63%) of probes belonged to class C hence being located in non CpG-rich regions, and other 7 were
from class  A  falling  in  CpG islands  (4)  and  shores  (3).  Regarding  the  architecture  of  genes,
observed alterations encompassed predominantly body of the genes (15) and 5’ untranslated regions
5’URT (7) overlapping with Exon-1 or transcriptional start site TSS respectively in 3 and 1 cases.
For majority of those genes (13) a link to neurological mechanisms and/or complications was found
in scientific literature and databases. Presented candidates require further investigation as well as
validation in independent cohorts and in broader spectrum of pain-related phenotypes. Example of
methylation plots for five most promising candidates are presented on Figures 7 - 11.
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Table 4 List of promising candidates that could be associated with neuropathic pain in type 2 diabetes mellitus.
SNP Gene symbol Gene part CpG Class Evidence  on association with neurological conditions
cg16513468 chr1: 154476659 rs542970632 TDRD10 5URT ClassA / S_Shore Hypo-methylated -
cg05848965 chr2: 174136765 MLK-AS1 Body ClassC Hypo-methylated -
cg21147282 chr7: 18868877 HDAC9 Body ClassC Hypo-methylated Involved in regulation of neuronal functions and in neurodegenerative processes (Majdzadeh et al., 2008)
cg00722325 chr7: 70044770 AUTS2 Body ClassC Hypo-methylated
Impicated in neuronal migration underling pathology of schizophrenia, ASD, epilepsy etc.  (Hori & Hoshino, 2017)
cg26777475 chr7: 100199952 rs537022088 ClassA / N_Shore Hypo-methylated Contribute to muscle degeneration in oculopharyngeal muscular dystrophy (Raz et al., 2013)
cg03808984 chr7: 102631307 FBXL13 Body ClassC Hypo-methylated Associated with spinocerebellar ataxia (GeneCards: FBXL13)
cg05119480 chr12: 104850745 rs143021773 CHST11 ClassA / Island Hypo-methylated Shown to be related to cerebral arteriovenous malformation in mouse (MGI: Chst11)
cg04543407 chr12: 110990222 PPTC7 Body ClassC Hypo-methylated -
cg08985029 chr12: 114843296 rs149450392 TBX5 5URT ClassA / Island Hypo-methylated -
cg13600488 chr13: 43385844 rs568188522 LINC01050 Body ClassC Hypo-methylated -
cg03533123 chr14: 55368924 rs534139027 GCH1 Body ClassA / Island Hypo-methylated Associated with dopa-responsive dystonia and Parkinson’s disease (Yoshino et al., 2018)
cg09630123 chr18: 76930760 rs145846343 ATP9B Body ClassC Hypo-methylated May contribute to Alzheimer’s Disease risk (Barber et al., 2015)
cg16254946 chr1: 54058616 GLIS1 Body ClassC Hyper-methylated May be associated with epilepsy (GeneCards: GLIS1)
cg25157472 chr3: 12996362 rs373678394 IQSEC1 Body ClassC Hyper-methylated Associated with intellectual disability and epilepsy  (Zerem et al., 2016)
cg23828851 chr3: 142296843 ATR Body ClassA / N_Shore Hyper-methylated Related to neurodevelopmental disorders (Lee et al., 2012)
cg23928123 chr10: 91063132 IFIT2 Body ClassC Hyper-methylated
-
cg11908751 chr11: 66790671 rs563475094 SYT12 ClassA / Island Hyper-methylated Linked to global parkinsonism (Tasaki et al., 2019)
cg00364287 chr12: 121570752 P2RX7 ClassC Hyper-methylated
Related to abnormal pain threshold in mouse (Sorge et al., 2012)
cg20640742 chr14: 58880253 TIMM9 ClassC Hyper-methylated






































Figure 7 Methylation loci  plot  of  cg00722325 CpG site within  AUTS2 gene.   The probe reached statistical  significance level  of  0.01 and presented concordant  direction of
methylation change in both PROPGER and PROPENG cohorts – hypo-methylation among PDN subjects.
Figure 8 Methylation loci  plot  of  cg03533123 CpG site within  GCH1 gene.   The probe reached statistical  significance  level  of  0.01 and presented  concordant  direction of
methylation change in both PROPGER and PROPENG cohorts – hypo-methylation among PDN subjects.
Figure 9 Methylation loci plot of cg09630123 CpG sites within  ATP9B gene.  The probe reached statistical significance level of 0.01 and presented concordant direction of
methylation change in both PROPGER and PROPENG cohorts – hypo-methylation among PDN subjects.
Figure 10 Methylation loci plot of cg25157472 CpG site within  IQSEC1 gene.  The probe reached statistical significance level of 0.01 and presented concordant direction of
methylation change in both PROPGER and PROPENG cohorts – hyper-methylation among PDN subjects.
Figure 11 Methylation loci plot of cg00364287 CpG site within  P2RX7 gene.  The probe reached statistical significance level of 0.01 and presented concordant direction of
methylation change in both PROPGER and PROPENG cohorts – hyper-methylation among PDN subjects.
Produced epigenome-wide data  allowed to have additionally  a  closer  look to  transient  receptor
potential  cation channel A1 (TRPA1) that was confirmed in number of methylation studies as a
pain-related  gene.  However,  the  results  on  our  cohorts  did  not  provide  any  evidence  on  its’
contribution  to  biological  mechanisms  linked  to  neuropathic  pain  in  studied  DN  cohorts.  As
reported in Table 5, none of CpGs located in the TRPA1 region reached the statistical significance
level when PDN and PLDN from the two considered cohorts were compared and the methylation
signals were inconsistent  between PROPGER and PROPENG (Figure  12).  Also in independent
dataset on migraine no evidence on differential methylation within TRPA1 gene was found. 
Table 5 List of CpG sites in a region of a gene TRPA1 and nominal p-values obtained in ANOVA test comparing painful DN 
individuals with painless patients in PROPGER and PROPENG cohorts, and comparing painful MOH, EM cases to healthy controls 
in headache cohort. Statistical significance level was defined at 1%. *probes assessed in the study of Sukenaga et al (Sukenaga et al., 




























TSS200 - - 0.918 0.371
cg14703605*/** chr8: 72987916 TSS200 0.411 0.067 0.171 0.612
cg27528660*/** chr8: 72987924 TSS200 0.407 0.835 0.432 0.862













TSS1500 0.286 0.798 0.900 0.235
Figure 12 Methylation loci plot of CpGs located in a region of TRPA1 gene.  None of the probes reached statistical significance level of 0.01 in any of the studied cohorts.
Interestingly,  identified  promising  genes  were  further  verified  in  three  independent  DNA
methylation datasets on pain-related conditions. In heat pain sensitiviy dataset 4 of 19 candidates
were found with at least 1 CpG site that reached the significance level at 1%. Remaining 13 genes
were not significant and 2 genes were excluded during preprocessing steps. In fibromyalgia dataset
already 14 candidates had at least 1 significant CpG, 3 genes did not reached significance level and
2 genes were filtered out in preprocessing pipeline. While in migraine dataset all 19 candidate genes
were present and for 9 at least 1 probe reached significance level.
Identified set of 27 CpG sites was used in multidimensional scaling that was applied to obtain a
visual  representation  of  distances  and  dissimilarities  between  PDN  and  PLDN  phenotypes
specifically observed in selected regions of the genome. In the analysis normalized beta values were
used as input. The results obtained for PROPGER and PROPENG cohorts are presented on Figure
13.  Although  the  perfect  separation  of  PDN  and  PLDN  was  not  obtained,  according  to
visualizations there was observed a trend for groups to separate in different directions indicating
that  the  selected  CpG  sites  are  able  to  highlight  the  presence  of  dissimilarities  between  two
phenotypes.
Figure 13 Results of principal component analysis carried out on normalized beta values within selected 27 CpG sites.
To further  explore obtained results,  analysis  of methylation  standard deviation  distribution  was
performed.  According  to  KS test  the  spread  of  normalized  and  filtered  beta  values  did  differ
between painful and painless patients in both PROPGER and PROPENG cohorts (p-value < 0.01).
In PROPENG dataset, the drift in standard deviation distribution was particularly notable in PLDN
group presenting significantly increased loss of coherence in methylation patterns in respect to PDN
individuals and showing shifted density curve (Figure 14).
Figure 14 Density  of  distribution  of  standard  deviation  after  logarithmic  transformation  Log(SD)  of  normalized
methylation beta values within PROPGER and PROPENG cohorts.
4.2. Evaluation of Biological Age
The performed analysis involved two cohorts of T2DM patients diagnosed with painful or painless
form of diabetic neuropathy: more numerous, selected from German population PROPGER cohort
and inferior in number, recruited from English population PROPENG cohort. Additional details on
both studied groups were provided respectively in Table 1 and Table 2. For each of the two cohorts
a battery of estimations of DNAm-based variables provided by Horvath’s epigenetic age calculator
were  analyzed: i) epigenetic  age  measures (DNAmAge,  DNAmAgeHannum,
DNAmAgeSkinBloodClock,  DNAmPhenoAge,  GrimAge);  ii)  telomere  length  estimation
(DNAmTL);  iii)  surrogates  of  protein  levels  in  plasma  (DNAmADM,  DNAmB2M,
DNAmCystatinC,  DNAmGDF15,  DNAmLeptin,  DNAmPAI1,  DNAmTIMP1);  iv)  prediction  of
number of cigarette packs smoked in one year (DNAmPACKYRS); v) blood cell counts (CD8T,
CD4T, CD8.naive, CD4.naive, CD8pCD28nCD45RAn, NK, Bcell, Mono, Gran, PlasmaBlast). The
differences in the parameters among phenotypic groups within PROPGER and PROPENG cohorts
were examined with multiple linear regression approach correcting for chronological age and sex.
PROPGER cohort 
DNAm-based estimates were analyzed in 70 painful and 65 painless age- and sex-matched DN
subjects from German population. Multiple linear regression results obtained for PROPGER cohort
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are presented in Table 7 in annexes. No significant differences in epigenetic age acceleration were
identified between painful and painless patients. However, considering nominal p-values and the
statistical significance level of 0.05, there were found the differences between PDN and PLDN in
estimates of  telomere  length  (DNAmTL  nominal  p-value  =  0.038).  In  painful  group  shorter
telomere  length  was  observed  compared  to  painless  subjects  as  visualized  on  Figure  15.  The
observed difference was not significant after BH correction for multiple tests. 
Figure 15 Association between chronological age and DNAm-based prediction of telomere length DNAmTL in painful
and painless DN in PROPGER cohort.  P-values of linear regressions for PDN and PLDN are reported.
PROPENG cohort 
27 PDN and 64 PLDN subjects from English population were compared regarding the differences
in DNAm-based estimates. The results from multiple linear regression analysis for all variables are
provided in Table 8 in annexes. There was found a significant difference (nominal p-value = 0.038)
in epigenetic age acceleration calculated with GrimAge model when painful and painless patients
were compared (Figure  16). PDN showed increased estimates of GrimAge regarding the PLDN
subjects.  The  differences  between  phenotype  groups  were  observed  also  in  DNAmTL  and
DNAmPAI1-  one  of  the  DNAmGrimAge  components.  The  predicted  telomere  length  was
significantly reduced in painful individuals comparing to painless (DNAmTL nominal p-value =
0.024)  while  PAI1 plasma levels  were  increased  (DNAmPAI1  nominal  p-value  =  0.020).  The
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visualization  of  associations  between  chronological  age  and  both  significant  DNAm-based
estimates in phenotypic groups of PROPENG cohort are provided respectively on Figures  17 and
18. None of the detected difference remained significant after multiple testing with BH procedure.
Figure 16 Epigenetic age difference (DNAmGrimAge – chronological age) adjusted for chronological age and sex in
the painful and painless groups in PROPENG cohort. Nominal p-values from multiple linear regression analysis are
reported.
33
Figure 17 Association between chronological age and DNAm-based prediction of telomere length DNAmTL in painful
and painless DN in PROPENG cohort.  P-values of linear regressions for PDN and PLDN are reported.
Figure 18 Association between chronological age and DNAm-based prediction of plasma levels of PAI1 in painful and
painless DN in PROPENG cohort.  P-values of linear regressions for PDN and PLDN are reported.
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5. Discussion
The  main  cause  of  morbidity  in  DM  is  neuropathic  pain,  affecting  performance  of  everyday
routines,  significantly  reducing  quality  of  sleep  and  life,  or  even  impeding  continuing  normal
functioning  and  accomplishing  usual  responsibilities. The  available  pain  treatments  are  still
unsatisfactory – they cope with low efficiency and serious side effects. Thus, the identification of
patients that are at  risk of developing NP and to adjust  the therapy according to the individual
responsiveness  to  analgesic,  could  improve  the  prevention,  management  and  quality  of  life  of
suffering patients.
To our knowledge, this is a pioneering study evaluating whole-genome DNA methylation in unique
populations of T2DM patients that were histopalogically diagnosed with diabetic neuropathy, with
or without neuropathic pain. We provided an evidence on the significant differences in methylation
patterns between painful and painless phenotypes.
Epigenomes of patients from two independent cohorts – PROPGER and PROPENG, were assessed
in whole blood samples with Infinium Methylation EPIC BeadChip. Produced whole-genome DNA
methylation data  allowed to perform differential  analysis  and to identify epigenetic  signals that
highlight the presence of dissimilarities between painful and painless subjects. We expanded our
study  estimating  epigenetic  age  of  the  patients  from  both  cohorts  and  evaluating  eventual
acceleration of biological age in PDN and PLDN phenotypes.
Regarding the differential  analysis, probes with altered methylation levels were identified using
validated pipeline that takes into consideration genomic context of CpG sites and their distribution
along the chromosomes. In order to select the most promising methylation signals that could be
plausibly associated with experience of NP, the filtering steps were applied. Thus, it was required
that short list of CpGs captures the regions reaching the significant methylation differences between
PDN and PLDN, presenting the methylation change > 1% in PROPGER and having the direction of
methylation change concordant between the two cohorts. With this approach  27 sites passed the
established filters  and 19 of them were genic,  resulting in a list  of 19 unique genes (Table  4).
Multidimensional scaling analysis confirmed the potential of generated set of CpG sites to separate
painful and painless subjects and to highlight the dissimilarities between two phenotypes.
Those differential epigenetic signals tended to be extended along genic regions and predominantly
involved genes of broadly considered neurological relevance. Among the most interesting genes,
AUTS2  gene was demonstrated to be involved in control of neuronal migration – a mechanism
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plausibly contributing to psychiatric disorders as schizophrenia or autism spectrum disorder (Hori &
Hoshino,  2017).  Mutations  in  another  interesting  candidate  gene  –  GCH1,  were  reported  as
increasing risk of dopa-responsive dystonia and Parkinson’s disease  (Yoshino et al., 2018), while
genetic variants within ATP9B could be associated with Alzheimer’s Disease (Barber et al., 2015).
A number of pathogenic variants within IQSEC2 was described and linked to disorders including
epilepsy and epileptic encephalopathy (Zerem et al., 2016). Yet interestingly, gene encoding P2X7
receptor  (P2X7R)  was  shown to  regulate  chronic  pain  sensitivity  through molecular  alterations
(Sorge et al., 2012).
Methylation level of TRPA1 gene was found different in independent studies (Sukenaga et al., 2016;
Takenaka et al., 2020) but this result was not confirmed in our cohort.  This may be due to the
distinct  clinical  phenotypes  of  studied  cohorts.  Indeed,  both  the  papers  considered  12  and  48
subjects respectively with age comparable to that of our cohort, with NP diagnosis but based on
either Douleur Neuropathique 4 questionnaire or the short-form McGill Pain questionnaire and not
on evaluation of histological biopsies, and without T2DM. Although methological approach used by
Sukenaga  and  Takenaka  was  different  from our  as  they  used  Illumina  HumanMethylation450
BeadChip instead of Infinium Methylation EPIC BeadChip, this factor apparently was not a source
of  major  discrepancies  between  assessed  CpG  sites  within  TRPA1 -  there  was  only  a  signle
methylation  probe  assessed  in  work  by  Sukenaga  that  was  not  present  in  EPIC  platform
(chr8:72988608  (hg19/GRCh37)).  However,  due  to  the  different  implemented  preprocessing
procedures, some of the probes present in cited studies were lacking in PROPGER and PROPENG
datasets since they were lost in the filtration steps of our pipeline. These explanation could be also
valid for missing reproducibility of the identified epigenetic pattern encompassing CpG sites within
TRPA1 gene in independent migraine-related methylation dataset from UNIBO.
Performed methylation standard deviation distribution analysis confirmed presence of epigenetic
drift and showed significantly increased loss of coherence in methylation patterns. However,  in
PROPENG cohort the observed shift was contrary to our expectations since painless group tended
to present higher state of dysregulation. The very reasonable explanation of this outcome is a fact
that PLDN group in PROPENG is significantly more advanced in chronological age comparing to
PDN. The increasing  discordance  of  methylome is  an individual,  non cell-specific,  widespread
phenomenon,  very  closely  related  to  age  (Jones  et  al.,  2015).  The  evidence  on  this  strong
association  came  from  range  of  the  studies  involving  embryonic  stem  cells,  cloned  mice,
monozygotic twin pairs or centenarians  (Fraga et al., 2005; Heyn et al., 2012; Humpherys et al.,
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2001;  Talens  et  al.,  2012). Epiegentic  drift  was  also  associated  with  age-related  disorders  as
Alzheimer’s  diseas  and geriatric  pathologies  (S.-C.  Wang et  al.,  2008).  Thus,  the notable  drift
visualized on Figure  14 plausibly reflects the difference in chronological age between PDN and
PLDN groups.
Regarding evaluation of biological aging, according to obtained results, there was no association
between painful phenotype and  acceleration of biological age expressed by  any of the assessed
epigenetic  clocks.  This  outcome  is  coherent  with  a  recent  study  investigating  DNAm-based
estimates  in  three  different  pain-related  phenotypes:  heat  pain  sensitivity,  fibromyalgia  and
headache (Kwiatkowska et al., 2020). Whereas, DNA methylation analysis involving limited group
of adults in advanced age provided evidence on accelerated biological age estimated with Horvath’s
clock in subjects suffering from chronic pain (Cruz-Almeida et al., 2019).
DNA methylation based prediction of telomere length (DNAmTL) was found to vary between PDN
and PLDN groups and this result was uniform among both studied cohorts. Particularly, calculated
telomere lengths were significantly shorter among painful subjects. Telomere length and epigenetic
alterations are two main features of aging and they are closely interacting players (Lee et al., 2019).
The length of telomers was shown to be associated with chronological age and with degenerative
diseases such as idiopathic pulmonary fibrosis, bone marrow failure, and cryptogenic liver cirrhosis
(Armanios,  2013).  Obtained  result  is  in  line  with  a  study  supporting  a  relationship  between
experience of chronic pain and reduced telomere length in women with fibromyalgia comparing to
healthy  controls  (Hassett  et  al.,  2012).  Another  work  related  to  fibromyalgia  showed negative
correlation  between  evaluative  dimension  of  pain  measured  in  patients  with  McGill  Pain
Questionnaire and DNAmTL (Kwiatkowska et al., 2020). Also in two other studies patients with
chronic knee osteoarthritis pain presented significantly shorter telomeres than individuals without or
with low pain levels (Sibille et al., 2012, 2017).
In PROPENG cohort  significant  difference  in  GrimAge –  i.e. a  measure  commonly  used  as  a
predictor of lifespan, between painful and painless subjects was detected. This observation plausibly
reflected the biological alterations occurred due to progressing diabetes since PDN group suffered
from diabetes  from significantly  longer  time.  The  results  identified  also  plasminogen  activator
inhibitor 1 (DNAmPAI1) as a plausible main actor of driving mechanism involved in progression of
T2DM and  contributing  to  observed  epigenetic  differences.  Similarly,  recently  published study
investigating epigenetic clocks in DN cohorts of patients with type 1 diabetes provided evidence on
significant acceleration of biological age expressed as GrimAge (Roshandel et al., 2020).
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As a consideration for future, we recognize that including in the analysis a control group free from
neuropathic pain, without diabetic neuropathy neither diabetes, would add an important insight and
would allow to obtain a more complete picture of this complex phenotype.
In conclusion, obtained results confirmed the presence of epigenetic differences between painful
and painless diabetic neuropathy patients. Promising genes were identified that may be linked to NP
through  DNA  methylation  mechanisms.  Selected  candidates  require  further  validation  in
independent DN cohorts, and in other populations of patients with pain-related phenotypes.
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Table 6 List of DNAm-based variables returned by the New DNA Methylation Age Calculator available online at https://dnamage.genetics.ucla.edu/. (Retrived from (Kwiatkowska et al., 
2020))
Variable name Variable description
DNAmAge DNAm age estimate based on methylation of 353 CpG sites described by Horvath et al. (Horvath, 2013)
DNAmAgeHannum DNAm age estimate based on methylation of 71 CpG sites described by Hannum et al. (Hannum et al., 2013)
DNAmAgeSkinBloodClock
DNAm age estimate (based on methylation of 391 CpG sites) for human fibroblasts, keratinocytes, buccal cells, endothelial
cells, lymphoblastoidcells, skin, blood, and saliva samples; devolped by (Horvath, 2013)
DNAmPhenoAge DNAm based estimate of phenotypic age (Levine et al., 2018)
DNAmGrimAge
DNA  methylation  age  model  build  on  eight  DNAm  based  measures  (DNAmADM,  DNAmB2M,  DNAmCystatinC,
DNAmGDF15, DNAmLeptin, DNAmPACKYRS, DNAmPAI1, DNAmTIMP1), chronological age and sex (Lu, Quach, et
al., 2019)
DNAmTL DNAm based estimate of telomere length (Lu, Seeboth, et al., 2019)
DNAmADM DNAm based prediction of plasma levels of adrenomedullin - a vasodilator peptide hormone (Lu, Quach, et al., 2019)
DNAmB2M
DNAm based prediction of plasma levels of beta-2 microglobulin - a component of major histocompatibility complex class
1 (MHC I) molecular (Lu, Quach, et al., 2019)
DNAmCystatinC
DNAm based prediction of plasma levels of cystatin C or (cystatin 3) – formerly called gamma trace, post-gamma-
globulin, or neuroendocrine basic polypeptide (Lu, Quach, et al., 2019)
DNAmGDF15 DNAm based prediction of plasma levels of GDF-15 - growth differentiation factor 15 (Lu, Quach, et al., 2019)
DNAmLeptin
DNAm based prediction of plasma levels of leptin - a hormone predominantly present in adipose cells (Lu, Quach, et al., 
2019)
DNAmPAI1
DNAm based prediction of plasma levels of plasminogen activator inhibitor antigen type 1 (PAI-1) - the major inhibitor of 
tissue-type plasminogen activator and unokinase plasminogen activator (Lu, Quach, et al., 2019)
DNAmTIMP1
DNAm based prediction of plasma levels of TIMP-1 or TIMP metallopeptidase inhibitor 1 - a tissue inhibitor of metallo-
proteinases (Lu, Quach, et al., 2019)
DNAmPACKYRS DNAm based prediction of a number of pack of cigarettes during year (Lu, Quach, et al., 2019)
CD8T DNAm based estimate of CD8 T cells, expressed as ordinal abundance measures (Houseman et al., 2012)
CD4T DNAm based estimate of CD4 T cells, expressed as ordinal abundance measures (Houseman et al., 2012)
CD8.naive DNAm based estimate of naive CD8 T cells, expressed as ordinal abundance measures (Horvath et al., 2016; Horvath &
Levine, 2015)
CD4.naive
DNAm based estimate of naive CD4 T cells, expressed as ordinal abundance measures (Horvath et al., 2016; Horvath & 
Levine, 2015)
CD8pCD28nCD45RAn
DNAm based estimate of  exhausted cytotoxic T defined as CD8+, CD28-, and CD45R- cells, expressed as ordinal 
abundance measures (Horvath et al., 2016; Horvath & Levine, 2015)
NK DNAm based estimate of natural killer cells, expressed as ordinal abundance measures (Houseman et al., 2012)
Bcell DNAm based estimate of B cells, expressed as ordinal abundance measures (Houseman et al., 2012)
Mono DNAm based estimate of monocytes, expressed as ordinal abundance measures (Houseman et al., 2012)
Gran DNAm based estimate of granulocytes, expressed as ordinal abundance measures (Houseman et al., 2012)
PlasmaBlast
DNAm based estimate of plasma blasts, expressed as ordinal abundance measures (Horvath et al., 2016; Horvath & 
Levine, 2015)
Table 7 Results of statistical hypothesis testing comparing painful and painless DN patients from PROPGER cohort with multiple
linear regression approach correcting for chronological age and sex. Linear model coefficient and corresponding p-values - nominal
and multiple tests corrected - are reported. P-values reaching significance level of 0.05 are reported in bold.
Epigenetic Variable Coefficient P-value_nominal P-value_AdjBH
DNAmAge -1.376 0.156 0.758
DNAmAgeHannum -1.517 0.191 0.758
DNAmAgeSkinBloodClock -0.661 0.295 0.758
DNAmPhenoAge -0.672 0.512 0.945
DNAmGrimAge 0.067 0.919 0.997
DNAmTL 0.053 0.038 0.651
DNAmADM 0.976 0.714 0.997
DNAmB2M -14609.644 0.277 0.758
DNAmCystatinC 2929.745 0.379 0.758
DNAmGDF15 27.554 0.356 0.758
DNAmLeptin -875.269 0.279 0.758
DNAmPAI1 -50.469 0.918 0.997
DNAmTIMP1 -35.417 0.713 0.997
DNAmPACKYRS -0.424 0.819 0.997
CD8T 0.007 0.311 0.758
CD4T -0.010 0.254 0.758
CD8.naive 9.980 0.054 0.651
CD4.naive -3.884 0.794 0.997
CD8pCD28nCD45RAn 0.002 0.997 0.997
NK 0.000 0.955 0.997
Bcell 0.004 0.329 0.758
Mono 0.003 0.552 0.946
Gran -0.002 0.855 0.997
PlasmaBlast -0.004 0.868 0.997
Table 8 Results of statistical hypothesis testing comparing painful and painless DN patients from PROPENG cohort with multiple
linear regression approach correcting for chronological age and sex. Linear model coefficient and corresponding p-values - nominal
and multiple tests corrected - are reported. P-values reaching significance level of 0.05 are reported in bold.
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Epigenetic Variable Coefficient P-value_nominal P-value_AdjBH
DNAmAge 0.652 0.433 0.612
DNAmAgeHannum -0.529 0.565 0.678
DNAmAgeSkinBloodClock -0.419 0.525 0.678
DNAmPhenoAge -1.872 0.140 0.372
DNAmGrimAge -1.827 0.038 0.304
DNAmTL 0.078 0.024 0.284
DNAmADM -3.736 0.171 0.372
DNAmB2M 5194.480 0.765 0.798
DNAmCystatinC -4000.534 0.339 0.612
DNAmGDF15 -24.393 0.414 0.612
DNAmLeptin -1123.137 0.156 0.372
DNAmPAI1 -1455.249 0.020 0.284
DNAmTIMP1 -64.820 0.619 0.688
DNAmPACKYRS -4.322 0.106 0.372
CD8T 0.016 0.070 0.338
CD4T -0.009 0.420 0.612
CD8.naive 3.851 0.550 0.678
CD4.naive 8.775 0.631 0.688
CD8pCD28nCD45RAn 1.602 0.057 0.338
NK 0.015 0.158 0.372
Bcell 0.004 0.319 0.612
Mono -0.001 0.820 0.820
Gran -0.029 0.167 0.372
PlasmaBlast -0.027 0.406 0.612
